High Level Meeting on AMR at the United Nations: A Debrief
Release Date: 10/26/2024
Best Papers in the Journal of Clinical Microbiology, 2024
Editors in Conversation
The past year in Clinical Microbiology, as seen through the lens of the Journal of Clinical Microbiology. Four JCM editors have each selected a paper they consider to be among the “best” we published in 2024. Of course there are no objective criteria for what makes a paper the “best.” So, by “best,” we mean “a paper that I find exciting.” View this episode: https://www.youtube.com/watch?v=fK9ZqZUrDiY Guests: , Johns Hopkins University School of Medicine ), Vanderbilt University Medical Center Links: Wood RC, Luabeya AK, Dragovich RB, Olson AM, Lochner KA, Weigel KM,...
info_outline
Best Papers of AAC, 2024
Editors in Conversation
2024 was a very active year on research in antimicrobial resistance, highlighted by an impactful and high level political declaration to combat antimicrobial resistance by the United Nations. In this episode, trainees from NIH-funded training program (T32) on antimicrobial resistance will help me discuss the most relevant research on the field in the year 2024. Welcome to editors in conversation! Topics discussed: The best papers of 2024 in gram-positive, gram-negative, mycobacterial and parasite resistance Guests: Nathalie Chen: University of Pittsburgh, Pittsburgh, PA Alex Kang: Houston...
info_outline
Getting a Job in a Clinical Microbiology Lab
Editors in Conversation
Looking for a dynamic and rewarding career? Learn what it means to be a Clinical Microbiology Laboratory Director and the necessary steps to get there. It’s a diverse job encompassing infectious diseases diagnostic testing, patient care, teaching, and research. This episode is geared for those who are interested in pursuing (or already have) a Ph.D. or M.D. Guests: Alexandra Bryson, Ph.D. Andrea Prinzi, Ph.D Links: for up to 50% off the publication fees when you publish in JCM or any of the ASM journals. This episode of Editors in Conversation is brought to you by the Journal of...
info_outline
The Global Antibiotic Research & Development Partnership (GARDP)
Editors in Conversation
Lack of access to antibiotics including those with enhanced activity against multidrug-resistant organisms is a major barrier to combat antimicrobial resistance, particularly in the developing world. Furthermore, discovering and making available new antimicrobial agents against the most pressing antibiotic-resitant organisms is a challenge due to multiple barriers. The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works...
info_outline
At-Home Collection and Testing for STIs
Editors in Conversation
So you want validated, at-home, self-collected swabs for STI testing… Here's what you need to know! Sexually transmitted infection rates continue to climb across the US and while testing for these diseases is widely available, for the most part it requires the patient to go to a local clinic to collect and submit their sample for testing. But, is that really necessary, especially from a test accuracy perspective? Today’s guests answer that exact question. And I’m sure that many, if not all of us would agree that the ability for patients to collect samples outside of a clinical...
info_outline
High Level Meeting on AMR at the United Nations: A Debrief
Editors in Conversation
The second High-Level Meeting on Antimicrobial Resistance (AMR) took place in New York on 26 September 2024 as the principal official, health-focused event during the UN General Assembly high-level week. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. A political declaration for the meeting was produced highlighting the fact that AMR will cause even more global suffering, particularly in low- and middle-income countries. In this episode we will debrief and analyze the possible impact of these meetings and consequences for the future of AMR...
info_outline
The Launch of ASM Case Reports Journal
Editors in Conversation
The American Society for Microbiology is launching a new journal, ASM Case Reports. The journal is already accepting submissions and will begin publishing in January of 2025. We discuss ASM Case Reports and what you can expect from this new journal. Watch this episode: Some of the questions we will discuss include: What is the scope of ASM Case Reports? What makes a case report or case series interesting and important? Why should people publish in ASM Case Reports? Guests: (twitter/𝕏) Learn more about ASM Case Reports Journal: Links: for up to 50% off the publication fees when...
info_outline
Heteroresistance: Mechanisms, Diagnosis and Clinical Implications
Editors in Conversation
Heteroresistance is a phenomenon that has been well characterized for many years. However, we are only now starting to understand its mechanistic basis. Indeed, the manner how bacteria respond to antibiotics is complex and phenomena such as persistance, tolerance may be overlapping with heteroresistance. Furthermore, heteroresistance seems to be common in real clinical scenarios and understanding its basis is likely to open new avenues on how we deploy antibacterials in clinical practice., Today, we have experts in the field to discuss this important topic. Watch this episode at...
info_outline
Microbiology in the Headlines: H5N1 in Dairy Cattle, The Plague, Measles, Neosporin and more!
Editors in Conversation
Join Dr. Ben Pinsky and Dr. Greg Berry as they dissect recent news stories, including the USDA's testing for H5N1 in ground beef and a surprising bubonic plague case in Oregon. They also tackle the resurgence of measles in the U.S., the local reappearance of malaria, and a curious study on Neosporin's potential to prevent viral infections. Overview: H5N1 Influenza Virus: Dr. Ben Pinsky provides an update on recent cases of H5N1 in humans and animals, including concerns about dairy cattle infections and the potential for human transmission. Bubonic Plague: Dr. Greg Berry discusses a recent...
info_outline
The Global Preclinical Antibacterial Pipeline
Editors in Conversation
The pipeline of antibiotic discovery is a major necessity due to the continuous evolution of resistance to currently used antimicrobials. This pipeline faces important challenges due to the lack of investment on antimicrobial research in the private sector and an economic model that discourages investment. In the last few years, however, encouraging signs are occurring but major gaps still remain. The World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline and the latest report is now available in the journal, lets discuss it! Watch this...
info_outlineThe second High-Level Meeting on Antimicrobial Resistance (AMR) took place in New York on 26 September 2024 as the principal official, health-focused event during the UN General Assembly high-level week. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. A political declaration for the meeting was produced highlighting the fact that AMR will cause even more global suffering, particularly in low- and middle-income countries. In this episode we will debrief and analyze the possible impact of these meetings and consequences for the future of AMR research and antimicrobial development.
Topics discussed:
- The political implications of the UN declaration on AMR.
- Comment of the scientific and public health impact of the declaration
- Elaborate on future antimicrobial research and development
Guests:
- John Rex, MD. Chief Medical Officer, F2G Ltd; Operating Partner, Advent Life Sciences
- Prabha Fernandes, PhD. Board Member of GARDP (Global Antibiotic Research and Development Partnership).
Links:
- HLM on AMR at UNGA: The end of the beginning
- 29 April 2024: “R&D Implications: Global Burden of Disease is 28% Infectious!”
- 27 Sep 2024: “Without action, AMR costs go from $66b to $159b/yr by 2050”
This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal.
Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.